Abstract
The inhibition of glycogen synthase kinase 3β (GSK3β) activity through pharmacological intervention represents a promising approach for treating challenging neurodegenerative disorders like Alzheimer's disease. Similarly, abnormal tau aggregate accumulation in neurons is a hallmark of various neurodegenerative diseases. We introduced new dual GSK3β/tau aggregation inhibitors due to the excellent clinical outcome of multitarget drugs. Compound
stands out among the synthesized inhibitors as a promising GSK3β inhibitor (IC
1.7 µM) with a pronounced tau anti-aggregation effect in a cell-based model of tauopathy. Concurrently,
was demonstrated to be non-toxic to normal cells, making it a promising neuroprotective lead compound that needs further investigation.